Bonafede M - Search Results

1

Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.

Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ. Bonafede M, et al. J Med Econ. 2015 May;18(5):376-89. doi: 10.3111/13696998.2014.1001849. Epub 2015 Jan 28. J Med Econ. 2015. PMID: 25530318 Free article.

2

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.

Bonafede M, Joseph GJ, Princic N, Harrison DJ. Bonafede M, et al. J Med Econ. 2013 Sep;16(9):1120-8. doi: 10.3111/13696998.2013.820192. Epub 2013 Jul 18. J Med Econ. 2013. PMID: 23808901 Free article.

3

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population.

Bonafede M, Joseph GJ, Shah N, Princic N, Harrison DJ. Bonafede M, et al. Clinicoecon Outcomes Res. 2014 Sep 15;6:381-8. doi: 10.2147/CEOR.S61445. eCollection 2014. Clinicoecon Outcomes Res. 2014. PMID: 25246804 Free PMC article.

4

Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis.

Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Bonafede M, et al. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1656-63. doi: 10.1002/acr.22638. Arthritis Care Res (Hoboken). 2015. PMID: 26097194 Free PMC article.

5

Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.

Bonafede M, Johnson BH, Shah N, Harrison DJ, Tang D, Stolshek BS. Bonafede M, et al. Am J Manag Care. 2018 Jul;24(8 Spec No.):SP279-SP285. Am J Manag Care. 2018. PMID: 30020740 Free article.

6

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Bonafede MM, et al. Adv Ther. 2012 Mar;29(3):234-48. doi: 10.1007/s12325-012-0007-y. Epub 2012 Mar 9. Adv Ther. 2012. PMID: 22411424

7

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Bonafede M, et al. Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8. Adv Ther. 2012. PMID: 22886712

8

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.

Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Bonafede M, et al. J Dermatolog Treat. 2013 Oct;24(5):369-73. doi: 10.3109/09546634.2012.755255. Epub 2013 May 21. J Dermatolog Treat. 2013. PMID: 23441722 Free PMC article.

9

Factors Associated with Direct Health Care Costs Among Patients with Migraine.

Bonafede M, Cai Q, Cappell K, Kim G, Sapra SJ, Shah N, Widnell K, Winner P, Desai P. Bonafede M, et al. J Manag Care Spec Pharm. 2017 Nov;23(11):1169-1176. doi: 10.18553/jmcp.2017.23.11.1169. J Manag Care Spec Pharm. 2017. PMID: 29083975 Free PMC article.

10

Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.

Kantor D, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH, Bonafede M. Kantor D, et al. Among authors: bonafede m. Clin Ther. 2020 Nov;42(11):2136-2147.e3. doi: 10.1016/j.clinthera.2020.09.014. Epub 2020 Nov 5. Clin Ther. 2020. PMID: 33160682

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

200 results

Search Page

Filters